招商通知： 2025年9月4-5日，第三届全球手术机器人大会 2025年7月16日， 微创医疗 发布《有关建议策略重组心律管理业务的不具约束力建议》的公告。根据该建议，微创医疗计划将 其CRM业务与微创心通医疗科技 有限公司（股份代号：02160）的业务进行合并 。 重组背景 微创医疗 是一家领先的医疗器械集团，业务涵盖心血管介入、骨科医疗器械、CRM、大动脉及外周血管介入、神经介入、结构性心脏病业务、手术机器人等多个 领域。其CRM业务专注于研发、制造及销售用于诊断、治疗及管理心律失常及心力衰竭的产品，包括 起搏器、除颤器、心脏再同步治疗装置及配套导线产品 。微 创心通则专注于结构性心脏病的经导管解决方案。 重组理由 建立心脏病产品平台 ：通过合并CRM业务和微创心通的业务，形成一个强大的心脏病产品平台，提供从CRM的起搏器、除颤器到结构性心脏病的全面产品 组合。 目前，该重组建议尚不具约束力，且未构成任何具约束力的要约、协议或承诺。 # 关于微创医疗 植入式心脏起搏器 共享国际营销及销售渠道 ：合并后可进一步共享及统筹全球市场资源，产生协同效应，扩大合作，建立更强的全球市场据点和影响力。 扩大业务规模及增 ...

其中，心通医疗一度跳空高开飙升近21%，但此后出现回落，截至发稿时间股价涨幅超过6%。 值得一提的是，心通医疗股价的异动上涨除了板块因素外，也和微创医疗（00853.HK）考虑将CRM业务并入心通医疗这则消息有关。 事实上，曾入选港股百强榜单的微创医疗也在今日出现异动，股价一度跳涨近7%。 微创医疗拟将CRM业务并入心通医疗 7月17日，生物医药B类股再度迎来普涨行情，三叶草生物-B（02197.HK）、科伦博泰生物（06990.HK）、心通医疗-B（02160.HK）等多股异动上涨。 其中，附属公司心通医疗是中国领先的结构性心脏病领域创新医疗器械企业，起源于2009年成立的瓣膜预研项目。 目前，心通医疗自主研发的经导管主动脉瓣植入（TAVI）系列及其手术配套产品已成功登陆全球20余个国家和地区的700余家核心医院，其中VitaFlow Liberty®经导管主动脉瓣膜及可回收输送系统于2024年成为国内首款自主研发并获欧盟CE认证的TAVI系统。 此外，心通医疗亦通过自主研发及与全球合作伙伴的共同研发，建立了涵盖经导管主动脉瓣、经导管二尖瓣、经导管三尖瓣和手术配件，以及左心耳 封堵器等产品的战略性研发布局。 ...

Core Viewpoint - The company is considering a non-binding proposal to restructure its CRM business by merging it with the operations of MicroPort Cardiac Rhythm Management, aiming to enhance competitiveness and create long-term value for stakeholders [1][2] Group 1: Business Overview - The company, along with its subsidiaries, is a leading medical device group focused on the innovation, manufacturing, and sales of high-end medical devices globally, with business segments including cardiovascular intervention, orthopedic medical devices, CRM, and others [1] - The CRM business is dedicated to developing global leading CRM solutions, primarily involved in the research, manufacturing, and sales of products for diagnosing, treating, and managing arrhythmias and heart failure, including pacemakers, defibrillators, and cardiac resynchronization therapy devices [1] Group 2: Strategic Benefits of the Merger - The merger of the two businesses will help establish a cardiac product platform, offering a diversified product line that includes CRM products and structural heart disease solutions, enhancing the company's global market development capabilities [2] - By merging the two businesses, the company aims to create synergies that will expand the scale and growth potential of the combined operations, improving revenue, profitability, and cash flow [2] - The unified financial management resulting from the merger will enhance capital efficiency and fundraising capabilities, while promoting the diversified product platform in international markets to increase recognition of the related value and growth potential [2]

Group 1 - The company is considering a non-binding proposal for a strategic restructuring of its CRM business to enhance internal resource integration and improve competitiveness [1] - The CRM business will potentially merge with the operations of MicroPort Cardiac Rhythm Management Co., Ltd., a non-wholly owned subsidiary listed on the Hong Kong Stock Exchange [1] - The company is a leading medical device group focused on the innovation, manufacturing, and sales of high-end medical devices globally, with various business segments including cardiovascular intervention and CRM [1] Group 2 - The CRM business aims to develop leading global CRM solutions, focusing on the research, manufacturing, and sales of products for diagnosing, treating, and managing arrhythmias and heart failure [1] - The product offerings include pacemakers, defibrillators, cardiac resynchronization therapy devices, and associated lead products, along with monitoring product combinations [1] - The structural heart disease business under MicroPort Cardiac Rhythm Management focuses on innovative transcatheter solutions and aims to provide advanced comprehensive solutions for treating structural heart diseases [2]